On September 23, 2010, Hansen, C. Henrik published a patent.Computed Properties of 890092-19-0 The title of the patent was Preparation of substituted 2-phenyl-3H-quinazolin-4-ones and analogs as antiinflammatory and cardiovascular agents. And the patent contained the following:
The invention is related to the preparation of 2-phenyl-3H-quinazolin-4-ones and analogs, e.g, 2-[4-(4-hydroxypiperidin-1-yl)phenyl]-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one (I), that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion mol.-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Thus, cyclization of 2-amino-4,6-dimethoxynicotinamide with 4-(4-hydroxypiperidin-1-yl)benzaldehyde gave pyridopyrimidinone I which caused a ≥ 20% inhibition in IL-6 mRNA and in VCAM-1 mRNA at a concentration ≤ 10 μM. Pharmaceutical compositions containing title compounds are also disclosed. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Computed Properties of 890092-19-0
The Article related to phenylquinazolinone preparation interleukin 6 proliferation inhibitor antiinflammatory cardiovascular, vascular cell adhesion mol 1 inhibitor phenylquinazolinone pyridopyrimidinone preparation and other aspects.Computed Properties of 890092-19-0
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics